Company Overview

SIGA Technologies, Inc. is a U.S.-based pharmaceutical company focused on the development and commercialization of therapeutics for health security and infectious diseases. The company operates primarily within the biodefense and antiviral pharmaceutical sectors, with a business model centered on supplying medical countermeasures to government agencies and preparedness programs. SIGA’s core commercial product is TPOXX (tecovirimat), an antiviral treatment approved in multiple jurisdictions for smallpox and related orthopoxvirus indications. Revenue has historically been heavily concentrated in procurement contracts with the U.S. government and international public health organizations.

The company was founded in 1995 and evolved from a broader biotechnology research platform into a specialized biodefense company following increased global focus on pandemic preparedness and national biosecurity initiatives. SIGA’s strategic positioning is tied to its regulatory approvals, intellectual property portfolio surrounding tecovirimat, and longstanding relationships with agencies such as the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA). The company has maintained a relatively focused operational structure compared with larger diversified pharmaceutical firms.

Business Operations

SIGA generates the majority of its revenue through the commercialization and government procurement of TPOXX under contracts associated with strategic national stockpiles and emergency preparedness programs. The company’s principal operating focus is its antiviral therapeutics business, particularly products targeting orthopoxviruses including smallpox and mpox. Commercial activity includes oral and intravenous formulations of tecovirimat, regulatory support activities, manufacturing oversight, and fulfillment of government procurement agreements.

Operations are primarily based in the United States, though SIGA has expanded internationally through supply agreements, regulatory filings, and distribution relationships in regions including Europe, Asia-Pacific, and the Middle East. The company relies on external manufacturing and supply-chain partners for production and logistics while maintaining control over product development, intellectual property, regulatory strategy, and government contracting activities. SIGA has collaborated with agencies such as BARDA and international public health authorities to support stockpiling and outbreak response initiatives.

Strategic Position & Investments

SIGA’s strategic direction has focused on expanding the global reach and regulatory footprint of TPOXX while pursuing additional opportunities in antiviral preparedness and biodefense. The company has invested in securing broader regulatory approvals and increasing procurement relationships with foreign governments and multilateral health organizations. Management has also emphasized maintaining manufacturing readiness and supply resilience to respond to emerging orthopoxvirus outbreaks and biodefense requirements.

The company’s investment profile remains concentrated rather than broadly diversified. Unlike larger pharmaceutical companies with extensive acquisition activity, SIGA has generally prioritized lifecycle management of tecovirimat and related intellectual property. Strategic initiatives have included development of intravenous formulations, pediatric labeling efforts, and expanded access pathways in international markets. Public disclosures indicate ongoing engagement with government-sponsored preparedness programs and potential expansion into related antiviral and infectious disease applications where scientifically and regulatorily appropriate.

Geographic Footprint

SIGA is headquartered in New York, United States, and conducts most of its core corporate, regulatory, and commercial operations domestically. Its principal customer base has historically included U.S. federal agencies associated with biodefense preparedness, including programs tied to the Strategic National Stockpile. The company’s operational influence is therefore strongly linked to U.S. public-sector healthcare and national security infrastructure.

Internationally, SIGA has expanded its presence through regulatory approvals and procurement arrangements in Europe, Canada, Asia-Pacific, and selected markets in the Middle East and Latin America. The company has pursued international commercialization opportunities related to orthopoxvirus preparedness and mpox response initiatives. While its global employee and infrastructure footprint is limited relative to multinational pharmaceutical peers, SIGA’s products have reached multiple continents through governmental and institutional procurement channels.

Leadership & Governance

SIGA’s leadership structure reflects its focus on regulatory execution, government contracting, and pharmaceutical commercialization within the biodefense sector. Governance oversight is provided through its board of directors and executive management team, with strategic emphasis on preparedness partnerships, operational efficiency, and long-term intellectual property protection. Public filings and investor communications indicate a leadership philosophy centered on disciplined capital allocation and maintaining readiness for public health emergency demand cycles.

Key executives include:

• Diem Nguyen, Ph.D. – Chief Executive Officer
• Robert L. Druskin – Chairman of the Board
• Tovah Barouch, CPA – Chief Financial Officer
• Dennis E. Hruby, Ph.D. – Former Executive Chairman and scientific leader associated with the development of tecovirimat
• David R. Wright – Chief Commercial Officer

The company’s governance and executive structure have historically emphasized experience in pharmaceuticals, finance, government procurement, and biodefense policy. Public company disclosures, including SEC filings, indicate continued focus on regulatory compliance, shareholder returns, and expansion of international public health partnerships.